Physician profile
Daniel L Eustace
NPI 1801825195
$486.69
in general payments reported to CMS, 2019-2025
14 companies · $17.60 in 2025
The $17.60 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $358 · 2022: $69.91 · 2023: $13.35 · 2024: $28.00 · 2025: $17.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $58.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $58.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $84.42 | 2021-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $79.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $64.34 | 2021-2022 | |
| Genentech USA, INC. | $38.87 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $36.74 | 2021 | |
| Biomerieux INC | $28.00 | 2024 | Biofire Respiratory Panel 2.1-Ez Eua, 30 Tests |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.22 | 2021 | |
| Lilly USA, LLC | $23.16 | 2021 | |
| Organon LLC | $22.06 | 2021 | |
| Amgen INC. | $20.02 | 2021 | |
| Abbott Laboratories | $19.81 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.31 | 2021 | |
| Glaxosmithkline, LLC. | $12.35 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Eustace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.